[Form 4] Aptevo Therapeutics Inc Insider Trading Activity

Rhea-AI Filing Summary

Aptevo Therapeutics director Harsanyi Zsolt was granted 7,200 restricted stock units (RSUs) on 08/06/2025. Each RSU converts one-for-one into common stock and is reported as a direct beneficial interest. The award carries a $0 price and vests in full on the first anniversary of the grant, meaning the holder would receive 7,200 common shares if vesting conditions are met. The reporting form lists a single reporting person and the grant was executed by an attorney-in-fact on behalf of the reporting person.

Positive

• Alignment of interests: Grant of 7,200 RSUs ties the director’s compensation to share performance through one-for-one conversion into common stock.
• Retention incentive: Full vesting after one year encourages continued service from the director.

Negative

• Potential dilution: The RSUs represent 7,200 potential shares upon vesting; the filing does not provide outstanding share count to assess materiality.
• Compensatory cost: The $0 price indicates a gratuitous grant that will be recorded as compensation expense for the issuer.

Insights

Corporate Governance Expert

TL;DR: Routine director equity award that aligns interests with shareholders; materiality depends on company share count.

The grant of 7,200 RSUs to a director is a standard compensation and retention tool. The RSUs convert 1:1 to common stock and vest in full after one year, creating a clear time-based retention incentive. The award is recorded as a direct beneficial interest and shows a $0 price, consistent with compensatory grants. Assessing investor impact requires the issuer's outstanding share count, which is not provided in this filing.

Securities Analyst

TL;DR: Adds 7,200 potential shares on vesting; modest in isolation but requires context to judge dilution.

The Form 4 reports an acquisition of 7,200 RSUs exercisable one-for-one into common stock and vesting in full on the first anniversary. The transaction is recorded as a direct holding and carries no exercise price, indicating a grant rather than a purchase. From a market perspective, the item is informational; its impact on EPS or ownership concentration cannot be determined from this filing alone because total shares outstanding and other recent insider activity are not disclosed here.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harsanyi Zsolt

(Last) (First) (Middle)

2401 4TH AVENUE

SUITE 1050

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/06/2025		A		7,200		(2)	(2)	Common Stock	7,200	$0	7,200	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

2. The RSUs vest in full on the first anniversary of the date of grant.

	/s/ SoYoung Kwon, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Harsanyi Zsolt report for APVO on this Form 4?

He was granted 7,200 RSUs on 08/06/2025, each converting 1:1 into common stock, reported as a direct beneficial interest.

How many APVO shares will be issued if the RSUs vest?

7,200 common shares will be issuable upon full vesting of the RSUs.

What is the vesting schedule for the RSUs?

The RSUs vest in full on the first anniversary of the grant date.

Did Harsanyi pay for the RSUs?

The filing shows a $0 price, indicating the RSUs were granted as compensation rather than purchased.

What is Harsanyi’s role at Aptevo (APVO)?

The reporting person, Harsanyi Zsolt, is identified as a Director of Aptevo Therapeutics.

Was the transaction reported under a Rule 10b5-1 trading plan?

The form does not indicate that the transaction was made pursuant to a Rule 10b5-1 plan.

Who signed the Form 4 on behalf of the reporting person?

The Form 4 signature block shows it was executed by attorney-in-fact SoYoung Kwon.